Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
Rudek MA, Bauer KS Jr, Lush RM 3rd, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD. Rudek MA, et al. Among authors: headlee dj. Ann Pharmacother. 2003 Oct;37(10):1369-74. doi: 10.1345/aph.1C404. Ann Pharmacother. 2003. PMID: 14519054 Clinical Trial.
Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N, Figg WD, Brawley OW, Bergan R, Cooper MR, Senderowicz A, Headlee D, Steinberg SM, Sutherland M, Patronas N, Sausville E, Linehan WM, Reed E, Sartor O. Dawson N, et al. Among authors: headlee d. Clin Cancer Res. 1998 Jan;4(1):37-44. Clin Cancer Res. 1998. PMID: 9516950 Clinical Trial.
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA. Messmann RA, et al. Among authors: headlee d. Clin Cancer Res. 2000 Apr;6(4):1302-13. Clin Cancer Res. 2000. PMID: 10778955 Clinical Trial.
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM. Sausville EA, et al. Among authors: headlee d. J Clin Oncol. 2001 Apr 15;19(8):2319-33. doi: 10.1200/JCO.2001.19.8.2319. J Clin Oncol. 2001. PMID: 11304786 Clinical Trial.
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA. Ryan QC, et al. Among authors: headlee d. J Clin Oncol. 2005 Jun 10;23(17):3912-22. doi: 10.1200/JCO.2005.02.188. Epub 2005 Apr 25. J Clin Oncol. 2005. PMID: 15851766 Clinical Trial.
37 results